Home › NDC Lookup › Drug shortages › Sufentanil Citrate Injection

Sufentanil Citrate Injection shortage

Sufentanil Citrate Injection is currently listed in shortage by the FDA. The FDA lists 4 affected products. The reported reason: Other. This page was last refreshed from FDA data on Sep 29, 2026.

Current ⚠ Supply risk: High Controlled substance Analgesia/Addiction, Pediatric 4 products 2 manufacturers 1,610 days · 4.4 yr First posted May 3, 2022 Updated Sep 22, 2026
Here’s the bottom line

Sufentanil citrate injection is in shortage, and Hikma is not currently making it. One of two manufacturers still lists some supply, but the 50 mcg/1 mL strength has no available source right now.

Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
4
Affected NDCs
2
Reporting manufacturers
1/2
Reporting mfrs supplying
1/2
Affected strengths supplied
75%
NDCs unavailable
1,610
Days in shortage
74
Medicaid Rx (2026)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 29, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Sufentanil Citrate Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
4 NDCs
Available 1 Unavailable 3
Affected strengths still supplied
Among manufacturers reporting this shortage
1/2 strengths
Sourceable 1 No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
1/2 makers
With supply 1 No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Sufentanil Citrate Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Plus 4 alternative dosage forms of Sufentanil Citrate.
See all other options & details →
Shortage timeline
  1. Sep 22, 2026
    Currently in shortage
    4 of 4 products affected.
  2. Sep 18, 2026
    FDA refreshed this shortage record
    3 products updated.
  3. May 3, 2022
    First reported to the FDA
    4 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
Current Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01) NDC 17478-0050-01 — Unavailable Not currently manufactured Other
Current Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05) NDC 17478-0050-05 — Unavailable Not currently manufactured Other
Current Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02) NDC 17478-0050-02 — Unavailable Not currently manufactured Other
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
Current Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21) NDC 00409-3382-21 — Available — —

These rows are manufacturer reports to the FDA for Sufentanil Citrate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Sufentanil Citrate Injection? options further down this page.

Why is Sufentanil Citrate Injection in shortage?

Right now, Hikma Pharmaceuticals is not manufacturing their versions of Sufentanil Citrate Injection 50 mcg/1 mL. The FDA has listed three of Hikma's specific package sizes as unavailable, and their note simply states "not currently manufactured." Unfortunately, Hikma did not share a more specific public reason for why production has stopped, so we don't have details beyond that.

It's worth knowing that this shortage report covers only the manufacturers who filed it with the FDA. In this case, Hospira (a Pfizer company) has reported that their 50 mcg/1 mL version is still available, so this is not a situation where every maker of this medicine has stopped producing it.

FDA reason code(s): Other

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Sufentanil Citrate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Sufentanil Citrate Injection?

Sufentanil Citrate Injection is currently on the FDA drug-shortage list. This medicine is given as an injection, so it is typically handled in a clinical setting rather than picked up as a prescription, but I want you to understand where supply stands.

The two entries on this record are very close in labeling, so please check carefully which one applies to you. The 50 ug/1 mL strength (from Hospira, a Pfizer company) is listed as available. The 50 mcg/1 mL strength (from Hikma) is listed as not currently manufactured, meaning there is no available source for that one right now. One of the two manufacturers on this record is still reporting supply.

The FDA lists the reason simply as "Other," and this situation has continued for more than a year. Even so, this reflects only the makers who filed this report.

  • Do not stop or change how this medicine is used on your own.
  • If your strength still has supply, ask your pharmacy or care team to order it — they can check wholesalers and other makers.
  • If your exact strength cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
  • Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls.

This is national, manufacturer-reported data and may not match local stock.

See “Where else can I get Sufentanil Citrate Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
  • This is a controlled substance. Transfers between pharmacies and switching strengths have extra federal/state rules — ask the pharmacy before you assume a transfer is possible.

Where else can I get Sufentanil Citrate Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Sufentanil Citrate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Alternative dosage forms of Sufentanil Citrate

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 3 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Sufentanil Citrate 50 ug/mLNDC 17478-0050-01 Akorn 10 ampules — AP Discontinued
Sufentanil Citrate 50 ug/mLNDC 17478-0050-05 Akorn 10 ampules — AP Discontinued
Sufentanil Citrate 50 ug/mLNDC 17478-0050-02 Akorn 10 ampules — AP Discontinued

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Sufentanil Citrate Injection — that fall in the same broad treatment class (opioid analgesic, anesthetic adjunct agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 004247
GCN 28880
HICL code 001749
Ingredient (HICL) Sufentanil Citrate
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H3
Therapeutic class — intermediate (HIC2) Analgesics
HIC3 code H3H
Therapeutic class — specific (HIC3) Opioid Analgesic, Anesthetic Adjunct Agents
AHFS code 28:08.08.00
AHFS class Opioid Agonists (28:08)
FDB label name SUFENTANIL 50 MCG/ML AMPULE
FDB brand name Sufentanil Citrate
Legend status F — Federal legend — prescription drug or device
DEA scheduleCII
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other analgesia/addiction, pediatric shortages

Sufentanil Citrate Injection shortage FAQs

Is Sufentanil Citrate Injection in shortage?
Yes — the FDA currently lists Sufentanil Citrate Injection in shortage (status: “Current”, first reported May 3, 2022). 4 of 4 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Why is Sufentanil Citrate Injection in shortage?
The manufacturer-reported reason on file with the FDA: Other.
Which products are affected?
Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01) (NDC 17478-0050-01); Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05) (NDC 17478-0050-05); Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02) (NDC 17478-0050-02). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Sufentanil Citrate Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Sufentanil Citrate somewhere?
4 alternative dosage forms of Sufentanil Citrate are also listed. See “Where else can I get Sufentanil Citrate Injection?” above — stock still varies by pharmacy.
What should I do if I take Sufentanil Citrate Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out. Because this is a controlled substance, transfers and substitutions have extra federal/state rules — ask the pharmacy first.

Still have a question about the Sufentanil Citrate Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages